Vaxiion begins VAX014 phase 1 trial in non-muscle invasive bladder cancer

TAGS

Vaxiion Therapeutics, a clinical stage biotech company based in California, has initiated a phase 1 clinical trial of its recombinant bacterial minicell-based oncolytic immunotherapy VAX014 for the treatment of non-muscle invasive bladder cancer (NMIBC).

The development comes following the conclusion of a 30-day review of the investigational new drug application (IND) of VAX014 by the US Food and Drug Administration (FDA).

According to Vaxiion Therapeutics, VAX014 is designed to selectively target a pair of cell-surface integrin heterodimers associated with non-muscle invasive bladder cancer.

Vaxiion begins VAX014 phase 1 trial in non-muscle invasive bladder cancer

Vaxiion begins VAX014 phase 1 trial in non-muscle invasive bladder cancer

The phase 1 trial of the oncolytic immunotherapy will assess its safety, tolerability and initial anti-tumor activity in non-muscle invasive bladder cancer patients. The early-stage trial will be a multi-center open label dose escalation study with dose expansion.

See also  Six Flags Hurricane Harbor Concord water park opens Splashwater Island

Matthew Giacalone – Vaxiion President said: “Advancing our first product candidate into clinical trials is a major milestone, signifying Vaxiion’s transition to a clinical stage company. We are now one step closer to achieving our ultimate goal of filling the unmet needs existing in the gaps of the current non-muscle invasive bladder cancer treatment algorithm.”

See also  What is the difference between Cancer and Tumor?

VAX014 had shown repeatedly demonstrated durable anti-tumor immunotherapeutic activity in preclinical models of non-muscle invasive bladder cancer and other types of cancer, resulting in overall tumor regressions and development of long-term anti-tumor immunologic memory.

The oncolytic immunotherapy was shown to be well tolerated after repeat dose administration in the clinically relevant dose range during its nonclinical safety studies.

See also  Novartis acquires biotech firm DTx Pharma to gain access to FALCON platform

The first-in-human phase 1 clinical trial of VAX014 includes two segments – a dose escalation segment and a dose expansion segment.

VAX014 is the first clinical product candidate developed from the recombinant bacterial-minicell delivery platform of Vaxiion Therapeutics.

CATEGORIES
TAGS
Share This